Mast Cell Activation Test for Hypersensitivity Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing immediate hypersensitivity reactions (IHR) to drugs are hindered by ethical and practical limitations, such as the risk of anaphylaxis and high costs associated with controlled graded drug challenges, and existing tests like skin tests and basophil activation tests have uncertainties and varying accuracy.
Innovation Solution
Mast cell activation tests (MATs) are used, where mast cells are contacted with patients' sera and then exposed to small compounds or drugs, detecting activation and degranulation to diagnose IHR, which can be performed with high analytical sensitivity and reliability, allowing for the discrimination between genuine IgE-mediated allergy and sensitization, and the assessment of cross-reactivity between structurally similar compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If controlled graded drug challenge is used to diagnose IHR, then diagnostic accuracy is improved, but ethical risks and practical costs increase
Solution Approach 1:
The patent uses basophils as intermediary cells to detect drug-specific IgE antibodies. Instead of directly challenging the patient with increasing drug doses, the method employs basophils that have been sensitized with the patient's serum to interact with the drug in vitro. This intermediary approach allows detection of hypersensitivity without exposing the patient to the full risk of anaphylaxis associated with direct drug challenges.
2Loss of time
If skin tests are used to diagnose IHR, then diagnostic speed is improved, but reliability and accuracy deteriorate
Solution Approach 1:
The patent replaces the mechanical skin test system with an in vitro basophil activation system. Instead of applying drugs to the patient's skin and observing local reactions, the method uses flow cytometry to detect basophil activation markers (CD63, CD203c) in blood samples. This substitution maintains rapid diagnostic capability while improving reliability by eliminating the uncertainties and off-target effects associated with skin testing.
3Measurement precision
If basophil activation test is used to diagnose IHR, then sensitivity for small compounds is improved, but requirement for fresh blood samples increases operational complexity
Solution Approach 1:
The patent performs preliminary sensitization of basophils with the patient's serum in vitro before exposing them to the drug. This preliminary action allows the basophils to be pre-loaded with patient-specific IgE antibodies, enabling the test to be performed on stored serum samples rather than requiring fresh blood draws. The method thus maintains high sensitivity for small compounds while reducing operational complexity by allowing batch processing of stored samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MATs provide a reliable and sensitive method for diagnosing IHR, with high sensitivity and specificity, enabling the identification of hypersensitivity to small compounds and drugs, and allowing for the study of immunological and functional cross-reactivity, thus improving diagnostic accuracy and safety.
Implementation Method 1
contacting mast cells with serum obtained from said subject; contacting the mast cells obtained in step (a) with said small compound or said drug; detecting mast cell activation and/or degranulation of the mast cells obtained in step (b)
Data Source
AI summary
Provided herein are in vitro methods for diagnosing an immediate hypersensitivity reaction (IHR) against a small compound or a drug in a subject, comprising the steps of (a) contacting mast cells with serum obtained from said subject; (b) contacting the mast cells obtained in step (a) with said small compound or said drug; (c) detecting mast cell activation and/or degranulation of the mast cells obtained in step (b); and (d) attributing the detection or no detection of mast cell activation and/or degranulation to a particular diagnosis of IHR.